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Chronic inflammation associated with chronic kidney disease
predicts all-cause and cardiovascular mortality in hemodialysis
patients. Here we sought to evaluate the association between
plasma levels of the inflammatory mediator interleukin-6
(IL-6) and mortality and aortic calcification/stiffness in
125 patients at different stages (2-5D) of chronic kidney
disease. Using multivariate linear regression, we found that
plasma IL-6 was independently associated with C-reactive
protein, albumin and the stage of chronic kidney disease,
but not the aortic calcification score or pulse wave velocity.
During follow-up studies (median of 829 days), 38 patients
died, 22 from cardiovascular events. Plasma IL-6 significantly
predicted overall and cardiovascular mortality; this
association persisted after multiple adjustments or restricting
the analysis to pre-dialysis patients. Moreover, IL-6 was a
significantly better predictor of mortality than C-reactive
protein, albumin or tumor necrosis factor-a. Hence, plasma
IL-6 independently predicted overall and cardiovascular
mortality in patients at different stages of chronic kidney
disease; however, whether lowering plasma
IL-6 will affect the outcome of chronic kidney disease
will require more direct evaluation.
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Cardiovascular disease is extremely prevalent in chronic
kidney disease (CKD) settings and accounts for the majority
of deaths in this population.1 It has been repeatedly
shown that advanced CKD is associated with a state of
chronic inflammation, as evidenced by either elevated levels of
various pro-inflammatory cytokines (IL-1b, IL-6, TNF-a, etc.)
or altered levels of acute-phase proteins (C-reactive
protein (CRP), albumin, fetuin-A, etc.).2–4 In addition to
individual genetic predispositions,5 the uremic state probably
increases the peripheral cell release of pro-inflammatory
cytokines and slows removal of the latter—resulting in a net
increase. Importantly, this chronic inflammation state has
been shown to predict all-cause and cardiovascular mortality
in hemodialysis patients,6–9 which suggests that high
inflammatory responsiveness to environmental stimuli may
determine the mortality risk in this population. However,
few studies have evaluated the inflammatory profile of
individuals at the earlier CKD stages10–12 and none of them
examined the association of this profile with outcomes in these
patients.
Interleukin-6 (IL-6) is a 26 kDa protein produced by
the liver. It is considered to be crucial in the acute-phase
inflammatory response and promotes lymphocyte activation
and proliferation, B-cell differentiation, leukocyte recruit-
ment and regulation of the synthesis of acute phase proteins,
fibrinogen, and albumin.13 Plasma levels of IL-6 are known to
be significantly higher in severely ill patients with acute renal
failure who die than in those who survive to hospital dis-
charge (independently of sepsis status).14 In addition,
in the elderly 15,16 and CKD patients on dialysis,17,18 plasma
IL-6 levels have been shown to better predict death than
IL-1b, TNF-a, CRP or albumin levels do. Hence, the aim of
this study in a cohort of patients at different CKD stages (2 to
5D) was to verify the association between plasma IL-6 levels
on one hand and mortality and two important cardiovascular
surrogate markers (namely aortic calcification and stiffness)
on the other.
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RESULTS
The distribution of IL-6 levels by CKD stage is depicted in
Figure 1. The IL-6 levels tended to rise as CKD progressed
with the increase becoming statistically significant at CKD
stages 5 and 5D. Further examination confirmed an inverse
linear relationship between IL-6 levels and the eGFR when
the analysis was restricted to pre-dialysis CKD patients at
stages 2–5, as shown in Figure 2.
Tables 1 and 2 show the main characteristics of the study
population, as a function of the median IL-6 plasma level.
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Figure 1 |Plasma IL-6 levels as a function of CKD stage.
*Po0.05 vs CKD stage 2; wPo0.05 vs CKD stages 2 and 3.
The dotted line indicates the mean normal value (1.32 pg/ml).
CKD, chronic kidney disease.
0 20 40 60 80 100
Glomerular filtration rate (ml/min/1.73 m2)
Lo
ga
rit
hm
ic 
no
rm
al
ize
d 
IL
-6
3
2
1
0
–1
Figure 2 | Linear regression curve. Relationship between
log-normalized plasma IL-6 levels and the estimated glomerular
filtration rate, for pre-dialysis stage 2–5 CKD patients (n¼ 82);
r2¼ 0.122; P¼ 0.001.
Table 1 |Main demographic and clinical characteristics, as a
function of the median plasma IL-6 levels
All
(n=125)
IL-6
p2.97pg/ml
(n=63)
IL-6
42.97 pg/ml
(n=62) P-value
Age (years) 67±12 65±13 70±11 0.031
Male gender n (%) 77(62) 37 (59) 40 (64) 0.506
Body mass index (kg/m2) 28±6 27±6 29±6 0.137
SBP (mmHg) 154±26 154±25 153±28 0.833
DBP (mmHg) 81±12 83±12 78±12 0.015
Pulse pressure (mmHg) 73±23 71±23 75±23 0.305
Diabetes n (%) 52 (42) 22 (35) 30 (48) 0.127
Smoking habit n (%)a 48 (40) 26 (41) 22 (38) 0.708
Presence of CVD n (%) 40 (32) 18 (29) 22 (35) 0.407
Framingham risk score 8.0±3.6 7.8±3.6 8.3±3.5 0.397
Current statin use n (%) 75 (60) 44 (70) 31 (50) 0.024
Current ACE/ARA-2
inhibitor use n (%)
74 (59) 44 (70) 30 (48) 0.015
CKD stage n (%) 0.002
2 8 (6.4) 7 (11.1) 1 (1.6)
3 33 (26.4) 23 (36.5) 10 (16.1)
4 31 (24.8) 16 (25.4) 15 (24.2)
5 10 (8) 3 (4.8) 7 (11.3)
5D 43 (34.4) 14 (22.2) 29 (46.8)
Central venous
access n (%)
9 (7.2) 7 (11.1) 2 (3.2) 0.164
Abbreviations: ACE, angiotensin-converting enzyme; ARA-2, angiotensin II type 1
receptor; CKD, chronic kidney disease; CVD, cardiovascular disease; DBP, diastolic
blood pressure; SBP, systolic blood pressure.
Data are means±s.d. or number (frequency) for binary variables.
an=121.
Table 2 |Main biochemical and vascular measurements as a function of the plasma IL-6 level (relative to the median).
All (n=125) IL-6 p2.97 pg/ml (n=63) IL-6 42.97 pg/ml (n=62) P-value
IL-6 (pg/ml) 5.25±7.89 (2.97; 1.5–6.1) 1.54±0.76 (1.6; 0.9–1.9) 9.03±9.87 (6.1; 4.1–9.7) —
Calcium (mmol/l) 2.30±0.18 2.32±0.15 2.27±0.20 0.171
Phosphate (mmol/l) 1.29±0.45 1.23±0.36 1.34±0.52 0.198
Intact-PTH (pg/ml) 139±142 (81; 46–173) 119±116 (71; 45–142) 161±163 (119; 58–194) 0.101
Hemoglobin (g/l) 12.0±1.7 12.4±1.4 11.5±1.8 0.003
Albumin (g/l) 37±6 39±6 35±5 o0.0001
C-reactive protein (mg/l) 10.4±23.1 (3.5; 1.3–8.9) 3.52±7.02 (1.5; 0.6–4.1) 17.4±30.6 (7.4; 3.4–20.1) o0.0001
TNF-a (pg/ml) 3.99±1.92 (3.6; 2.2–5.1) 3.80±1.79 (3.3; 2.2–5.1) 4.2±2.04 (4.1; 2.5–5.1) 0.193
Total cholesterol (mmol/l) 4.9±1.1 5.0±1.0 4.8±1.2 0.412
HDL cholesterol (mmol/l) 1.34±0.5 1.40±0.5 1.28±0.5 0.180
Triglycerides (mmol/l) 2.05±1.35 1.78±0.1 2.35±1.6 0.024
Aortic calcification score (%)a 3.18±3.11 (2.2; 0.8–4.4) 2.72±2.95 (1.5; 0.6–4.0) 3.63±3.22 (2.6; 0.9–5.3) 0.070
PWV (m/s) 15±4 14±3 16±4 0.007
Abbreviations: HDL, high-density lipoprotein; PTH, parathyroid hormone; PWV, pulse wave velocity; TNF, tumor necrosis factor. Data are means±s.d. and (median;
percentile 25–75) for variables with non-Gaussian distribution.
an=108.
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Patients with plasma IL-6 42.97 pg/ml were significantly
older, had lower diastolic blood pressure, were less likely to
be treated with statins and angiotensin-converting enzyme
(ACE)/angiotensin II type 1 receptor (ARA-2) inhibitors and
were more likely to suffer from late-stage CKD (that is, 5 and
5D). These patients had higher CRP and triglyceride levels
and significantly lower hemoglobin and albumin levels. They
had higher pulse wave velocity (PWV) values and tended to
have higher aortic calcification scores.
In univariate linear regression analyses, CRP (r2¼ 0.435;
Po0.0001), triglyceride (r2¼ 0.042; b¼ 0.156; P¼ 0.024)
and intact PTH levels (r2¼ 0.035; P¼ 0.039), and the CKD
stage (r2¼ 0.144; Po0.0001) were directly associated with
higher plasma IL-6 levels. Conversely, albumin (r2¼ 0.198;
Po0.0001), hemoglobin (r2¼ 0.084; P¼ 0.001) and calcium
levels (r2¼ 0.034; P¼ 0.041) and ongoing use of ACE/ARA-2
inhibitors (r2¼ 0.064; P¼ 0.005) and statins (r2¼ 0.028;
P¼ 0.06) were inversely associated with plasma IL-6 levels.
There was no significant linear correlation between plasma
IL-6 levels and the aortic calcification score or the PWV. In a
multivariate linear regression analysis, only CRP, albumin
and the CKD stage were found to be independently
associated with plasma IL-6 levels, as detailed in Table 3.
During the follow-up period (mean: 786±301 days;
median: 829; range: 10–1119), 38 patients died (22 from
CV events (unknown cause or sudden death (n¼ 13), stroke
(n¼ 3), myocardial infarction (n¼ 1), congestive cardiac
failure (n¼ 3), ventricular arrhythmias (n¼ 2)), eight from
infectious diseases and eight from other causes). In a crude
analysis, the IL-6 plasma level predicted overall (Figure 3a)
and cardiovascular mortality (Figure 3b) (P¼ 0.002 and
P¼ 0.003 in the log-rank comparison between the curves,
respectively). Table 4 shows the results of the Cox regression
analyses, which confirmed that plasma IL-6 was still a
predictor of mortality (either entered as a continuous
variable or stratified by the median) after adjustment for
other variables that have also been shown to significantly
influence the mortality risk in this population (age, per 1 year
increase, RR¼ 1.05; P¼ 0.004; hemoglobin, per 1 g/l in-
crease, RR¼ 0.73, P¼ 0.002; aortic calcification score, per 1
unit increase, RR¼ 1.24, P¼ 0.0003; CKD stage, RR¼ 1.73,
P¼ 0.010). Similar results were found when considering IL-6
levels stratified by quartile (3rd quartile: RR¼ 4.4, 95%
CI¼ 1.25–15.5, P¼ 0.021 and 4th quartile: RR¼ 6.3, 95%
CI¼ 1.8–21.9, P¼ 0.004). An additional Cox regression
model including the calculated propensity score (by median
and to better adjust for confounders, as detailed in the
methodology section) confirmed IL-6 as an independent
predictor of overall mortality, both when entered as a
continuous variable (RR¼ 1.588, 95% CI¼ 1.069–2.36, per 1
s.d. increment) or categorized by the median (RR¼ 2.23,
95% CI¼ 1.030–5.064, for IL-642.97 pg/ml). When restrict-
ing the analysis to stage 2–5 pre-dialysis CKD patients,
plasma IL-6 levels remained a predictor of overall and
cardiovascular mortality, in both crude analysis (log-rank
P¼ 0.009 and P¼ 0.02, respectively) (Figure 4) and the Cox
regression analysis (Table 5). An additional analysis con-
firmed plasma IL-6 as a better predictor of death than the
three other acute inflammatory response markers assayed in
the study (CRP, albumin and TNF-a), when either consider-
ing all patients (Table 6) or restricting the analysis to pre-
dialysis CKD patients at stages 2–5 (data not shown).
DISCUSSION
In this study, we showed that plasma levels of IL-6 augment
with CKD stage (particularly at CKD stages 5 and 5D).
Table 3 |Multivariate linear regression analysis—variables
independently associated with plasma IL-6 levels
(log-normalized)
b (95% CI) P-value
CKD stage 0.182 (0.085–0.279) o0.0001
Albumin 0.038 (0.060 to 0.016) 0.001
C-reactive protein (log-normalized) 0.380 (0.288–0.473) o0.0001
Abbreviations: CI, confidence interval; CKD, chronic kidney disease; PTH, parathyroid
hormone.
Variables entered in the model: C-reactive protein, albumin, CKD stage, hemoglobin,
current ACE/ARA-2 inhibitor use, triglycerides, intact-PTH (log-normalized), calcium;
r2 for the model=0.56.
P =0.002
IL-6 > 2.97 pg/ml
IL-6 > 2.97 pg/ml
IL-6 ≤2.97 pg/ml
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Figure 3 |Crude analyses of mortality. (a) Kaplan–Meyer
estimates of overall mortality for all patients (n¼ 125) as a
function of median plasma IL-6 levels. (b) Kaplan–Meyer estimates
of cardiovascular mortality for all patients (n¼ 125)
as a function of median plasma IL-6 levels.
Table 4 | Univariate and multivariate Cox regression analysis
of risk factors at baseline for all-cause mortality
Models of patient survival (event n=38) RR 95% CI P-value
Unadjusted
IL-6a 2.837 1.406–5.726 0.004
Log-normalized IL-6b 1.748c 1.258–2.431 0.001
Model 1d
IL-6a 2.352 1.035–5.343 0.041
Log-normalized IL-6b 1.670c 1.113–2.504 0.013
Abbreviations: CI, confidence interval; RR, risk ratio.
aIL-6 entered as categorical variable (IL-642.97 pg/ml vs IL-6p2.97 pg/ml; median).
bIL-6 entered as continuous variable.
cSummarizing the risk of a 1-s.d. (1.025, that is, 2.787 pg/ml) increment in
log-normalized IL-6.
dModel 1: adjusted for age, hemoglobin, aortic calcification score, CKD stage.
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Importantly, plasma IL-6 levels predicted overall and
cardiovascular mortality, even after adjusting for several
covariates (that is, age, serum hemoglobin levels, aortic
calcification score, and CKD stage) or restricting the analysis
to the pre-dialysis CKD patients at stages 2–5. Lastly, plasma
IL-6’s power to predict mortality was greater than three other
important biomarkers of inflammation assayed in the study
cohort, namely CRP, TNF-a, and albumin.
The pathological pathway underlying the chronic inflam-
mation state associated with uremia is still poorly under-
stood. Even though various dialysis-related factors (for
example, poor dialyzer membrane biocompatibility, dialysate
contamination, type of vascular access, etc.) may promote a
persistent, low-grade inflammatory response, the present
data showing augmented plasma IL-6 levels in earlier CKD
stages suggest that the role of loss of kidney function or the
kidney disease etiology are at least as important in
modulating inflammation or inflammation mediators. It is
possible that uremia activates inflammation and/or triggers a
reduction in the renal clearance of pro-inflammatory
cytokines. Moreover, advanced age and diabetic status (both
of which are factors known to contribute to sustained
inflammatory activity) were not associated with plasma
IL-6 levels in the study population, which substantiates the
effect of renal dysfunction. In a previous cross-sectional
study including CKD stage 5 and 5D patients, individuals
with stable angina and normal renal function and healthy
controls, it was reported that serum creatinine was the sole
independent determinant of plasma IL-6 levels.11 Conversely,
and in contrast to our own findings, the only other study to
have evaluated plasma IL-6 levels in patients at earlier CKD
stages (3–5) found that this interleukin was significantly
elevated in the CKD patients (compared with healthy
controls), but that there was no association with the
estimated glomerular filtration rate (GFR).12 This divergence
most probably reflects the effects of the latter study’s small
sample size (n¼ 60) and/or differences in the IL-6 assay and
GFR estimation.12
The epidemiological association between plasma IL-6
levels and mortality has repeatedly been reported in different
sub settings in both the general population19,20 and
hemodialysis patients.9,14,18,21 However, to the best of our
knowledge, this is the first study to report such an association
in a cohort including patients at earlier (pre-dialysis) CKD
stages. In this respect, there is much evidence to suggest that
pre-dialysis CKD patients are also at a greater risk of
cardiovascular disease and the associated morbidity and
mortality. Notably, most patients with CKD stages 3–5 will
die of cardiovascular complications before developing end-
stage renal disease.22 Recent reports indicate that IL-6 might
be involved in cardiovascular pathologies—perhaps even
directly by affecting the atherosclerotic burden, as high
plasma IL-6 levels have been related to the risk of coronary
death and major coronary events in patients with unstable
angina.23,24 Furthermore, IL-6 mRNA has been detected in
coronary plaque samples obtained from patients having
undergone heart transplantation or atherectomy.25 Accord-
ingly, in an experimental model of Apo-E-deficient mice, it
has been shown that the injection of recombinant IL-6
accelerated atherosclerosis.26 This hypothesis is corroborated
by the fact that higher plasma IL-6 levels predict the risk
of future myocardial infarction among apparently healthy
Table 5 | Univariate and multivariate Cox regression
analysis of risk factors at baseline for all-cause mortality
in pre-dialysis CKD patients stages 2–5 (n=82)
Models of patient survival (event n=18) RR 95% CI P-value
Unadjusted
IL-6a 3.945 1.298–11.995 0.016
Log-normalized IL-6b 2.04c 1.187–3.525 0.010
Model 1d
IL-6a 4.20 1.190–14.829 0.026
Log-normalized IL-6b 2.118c 1.138–3.942 0.018
Abbreviations: CI, confidence interval; CKD, chronic kidney disease; RR, risk ratio.
aIL-6 entered as categorical variable (IL-642.42 pg/ml vs IL-6p2.42 pg/ml; median).
bIL-6 entered as a continuous variable.
cSummarizing the risk of a 1-s.d. (1.025, that is, 2.787 pg/ml) increment in
log-normalized IL-6.
dModel 1: adjusted for age and aortic calcification score.
Table 6 | Relative risk for albumin, CRP and IL-6 to mortality
in a Cox proportional hazard (n=125)
Hazard ratio (95% confidence interval)
Univariate P-value Multivariatea P-value
Albumin 0.959 (0.912–1.009) 0.104 0.929 (0.874–0.986) 0.016
Log-normalized CRP 1.245 (1.004–1.543) 0.046 1.194 (0.943–1.512) 0.140
Log-normalized TNF 1.159 (0.546–2.459) 0.702 0.798 (0.355–1.791) 0.584
Log-normalized IL-6 1.725 (1.251–2.378) 0.001 1.700 (1.158–2.495) 0.007
Abbreviations: CKD, chronic kidney disease; CRP, C-reactive protein; TNF, tumor
necrosis factor.
aAdjusted variables included age, CKD stage, and aortic calcification score in each
biomarker model.
P =0.009
IL-6 > 2.42 pg/ml
IL-6 > 2.42 pg/ml
IL-6 ≤ 2.42 pg/ml
IL-6 ≤ 2.42 pg/ml
IL-6 > 2.42 pg/ml
IL-6 ≤ 2.42 pg/ml
P =0.02
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Figure 4 |Crude analysis of mortality in pre-dialysis patients.
(a) Kaplan–Meyer estimates of overall mortality for patients
at CKD stages 2–5 (n¼ 82) as a function of median plasma
IL-6 levels. (b) Kaplan–Meyer estimates of cardiovascular mortality
for patients at CKD stages 2–5 (n¼ 82) as a function of median
plasma IL-6 levels.
Kidney International (2010) 77, 550–556 553
DV Barreto et al.: IL-6 and mortality in CKD o r ig ina l a r t i c l e
men20 and have been associated with severe congestive heart
failure.25,27 In hemodialysis patients, a positive association
has been reported between plasma IL-6 levels and carotid
intima-media thickness but not the presence of carotid
plaque.2 Furthermore, in a small peritoneal dialysis cohort,
Stompor et al.28 found a significant, positive association
between plasma IL-6 levels and PWV. In this study, we found
that patients with higher IL-6 levels presented significantly
higher PWV and a trend towards a higher aortic calcification
score. Nevertheless, the fact that the observations were not
maintained in the subsequent linear regression analyses
implies that the relationship between IL-6 and these vascular
parameters is rather weak and suggests that the main effect of
IL-6 on the risk of mortality in this cohort was independent
of vascular calcification and stiffness. As the majority of
cardiovascular deaths in our cohort were ascribed as
unknown cause or sudden death, this might imply a link
between plasma IL-6 and plaque rupture/sudden death.
The finding that plasma IL-6 levels were able to
independently predict mortality in both advanced and
early-stage CKD raises a key question: are there any active
measures or interventions that might reset this cytokine
imbalance from the very initial stages of CKD onwards?
In this respect, it is important to note that some of the drugs
that are commonly administered to CKD patients (that is,
statins and ACE/ARA-2 inhibitors) have been shown to have
major anti-inflammatory effects and also decrease IL-6 levels
in both non-renal patients with coronary artery disease29,30
or essential hypertension31 and CKD patients.32,33 In this
study, use of statins and ACE/ARA-2 inhibitors was higher in
the group with lower IL-6 levels, in agreement with the above
hypothesis. Although other factors (for example, different
therapeutic approaches, depending on the degree of renal
dysfunction) may also have a role, it should be considered
that interventional measures targeting a reduction in IL-6
levels could possibly reduce the unacceptably high cardio-
vascular mortality observed in the uremic population. It is
noteworthy that statin administration lowered CRP levels
(compared with placebo) but had no impact on outcomes in
a diabetic, hemodialyzed population.34 Furthermore, statin
use in non-diabetic hemodialysis patients, decreased CRP
levels but did not improve outcomes;35 however, one must
consider that in this final stage of CKD, the vascular damage
might have become irreversible.
Limitations of this study include the relatively small
sample size and the fact that we relied on a single blood
sample (and thus cannot take into account any potential
variations over time in IL-6 levels). Nevertheless, in this
respect, Pupim et al.36 monitored a cohort of incident
hemodialysis patients over 12 months and found that
although these individuals had significantly higher plasma
IL-6 levels than healthy controls, there were no significant
changes in repeated measurements of plasma IL-6 levels over
the study period. All trends toward variation over time were
dependent on the initial baseline values. It is possible that
plasma IL-6 levels behave similarly in the pre-dialysis setting;
hence, additional studies evaluating within-subject variation
would be of great value. On the other hand, the strengths of
this study include the fact that we evaluated the effect of a
potentially modifiable condition (inflammatory state) on a
hard outcome parameter (mortality) and on two important
surrogate cardiovascular markers in patients at different CKD
stages.
In conclusion, plasma levels of IL-6 are significantly
elevated in advanced CKD and independently predict overall
and cardiovascular mortality in a cohort of patients at
different CKD stages with greater prediction power than the
three other evaluated acute phase proteins (CRP, TNF-a, and
albumin). Further studies evaluating the effect of commonly
used drugs with proven anti-inflammatory activities (such as
statins and ACE/ARA-2 inhibitors) on plasma IL-6 levels and
associated outcomes in a CKD setting, particularly in pre-
dialysis patients, are warranted.
PATIENTS AND METHODS
Patient selection
Over an 18-month period (from January 2006 to June 2007), a total
of 150 Caucasian CKD patients were recruited from the Nephrology
Department’s clinic at Amiens University Hospital. All patients gave
their informed, written consent. The study was approved by the
local Institutional Review Board and performed in accordance with
the ethical principles of the Declaration of Helsinki.
Included patients had to be above the age of 40 years, with a
confirmed diagnosis of CKD (defined as being on hemodialysis or
having two previous, estimated creatinine clearances—calculated
according to the Cockcroft and Gault formula37—with an interval
of 3–6 months and valueso90ml/min per 1.73m2). Stage 5D CKD
patients had been receiving thrice-weekly hemodialysis for at least
3 months. The presence of chronic inflammatory disease, atrial
fibrillation, complete heart block, abdominal aorta aneurysm, an
aortic and/or femoral artery prosthesis, primary hyperparathyroid-
ism, kidney transplantation or any acute cardiovascular event in the
3 months before screening were non-inclusion criteria. The 125
patients who met all inclusion criteria and had available IL-6 assay
results were analyzed. The 25 patients who were not included in the
analyses did not differ from the analyzed ones in terms of age,
gender, diabetes, previous cardiovascular disease status, body mass
index, or CKD stage distribution.
Study protocol
All patients were hospitalized for the day to perform laboratory
blood tests, blood pressure measurements, PWV determinations,
and multislice spiral computed tomography scanning. Hemodialysis
patients were seen on a dialysis-free day or in the morning before the
dialysis session. A patient interview focused on comorbidities and
the personal disease history (especially previous vascular events).
The patients’ medical files were reviewed to record any concomitant
medications. For descriptive purposes, patients who reported
current or past use of insulin and/or oral hypoglycemic drugs were
considered to be diabetics. Previous CVD was defined as a history of
any of the following events: myocardial infarction, stroke, heart
failure, angina pectoris, or surgical procedures for angina or
coronary/peripheral artery disease (including percutaneous trans-
luminal angioplasty). The Framingham risk score38 was calculated
for every patient.
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Laboratory tests
Blood samples were collected on the same morning, before other
investigations. Selected assays were performed after the samples had
been frozen and stored at 801C. Serum calcium, phosphate,
cholesterol, hemoglobin, and creatinine were assayed in an on-site
biochemistry laboratory using standard auto-analyzer techniques
(Modular IIP system, Roche Diagnostics, Basel, Switzerland). Serum
intact PTH was determined in a chemiluminometric immunoassay
(Liaison N-tact PTH CLIA, Diasorin, Stillwater, USA). TNF-a
plasma levels (2.88 pg/ml, ranging from non-detectable to 5.89 pg/
ml) and IL-6 plasma levels were determined by ELISAs (R&D
Systems, Wiesbaden, Germany). The limit of detection of the IL-6
ELISA is 0.48 pg/ml and the highest reference standard is 1500 pg/
ml. Values below the limit of detection were considered to include
the minimum detectable concentration (0.48 pg/ml). Values above
the highest standard were not included. All data came from a single
determination. Normal values in EDTA-plasma were those stated by
the manufacturer (mean of n¼ 38: 1.32 pg/ml; range: ND-4.70 pg/
ml). CRP (normal value 2.87mg/l, ranging from non-detectable to
3.0mg/l) albumin and cystatin C (CysC) serum levels were
determined by laser nephelometry (BNProSpec, Siemens Healthcare,
Dade Behring, Marburg, Germany). To describe the true GFR as
closely as possible, the estimated GFR combining Scr and CysC
measurements (CKD-epi) was calculated for all non-dialyzed
patients according to the following, recently published ‘CKD-epi’
equation:39 177.6 Scr0.65CysC0.57 age0.20 (0.82 if female
patient). Patients were then classified into CKD stages, according to
the National Kidney Foundation’s K/DOQI guidelines.22
Pulse wave velocity evaluation
Carotid-femoral PWV was determined automatically with a
dedicated, validated device (Complior Colson, Createch Industrie,
Massy, France), as previously detailed elsewhere.40,41
Multislice spiral computed tomography
To quantify the presence and extent of aortic calcifications, each
patient underwent an multislice spiral computed tomography scan.
All examinations were performed with a 64-detector CT scanner
(Lightspeed VCT, GE Healthcare, Milwaukee, WI, USA). Detailed
technical information on the procedure has been provided else-
where.40
Survival
Death records were made prospectively, by considering all patients
included at least 20 months before the study end date (March 1st,
2009). Each medical chart was reviewed and the cause of death was
assigned by a physician on the basis of available clinical information.
For out-of-hospital deaths, the patient’s general practitioner was
interviewed to gain pertinent information on the cause. Cardiovas-
cular mortality was defined as any death directly related to a
cardiovascular system dysfunction (stroke, myocardial infarction,
congestive cardiac failure, sudden death, or death from an unknown
cause).
Statistical analyses
Data are expressed as the mean±s.d., median and range or
frequency. For analytical purposes, patients were stratified according
to the median plasma IL-6 (2.97 pg/ml). Intergroup comparisons
were performed using a w2-test for categorical variables and the
Student’s t-test or the Mann–Whitney test for continuous variables.
Renal function was considered either as the estimated GFR (in
analyses restricted to pre-dialysis patients) or the CKD stage entered
as a continuous variable (recoded from 2 to 6, with 6 meaning CKD
stage 5D patients). Univariate linear regression analyses were
performed to evaluate the association between plasma IL-6 and
selected demographic, biochemical and clinical variables. Thereafter,
a multiple linear regression analysis of the factors selected in the
univariate analysis was carried out to identify those independently
associated with plasma IL-6. The Kaplan–Meyer actuarial method
was used to estimate overall survival for the IL-6 median. The log-
rank test was used to compare survival curves. Univariate and
multivariate analyses of mortality were performed by using a Cox
proportional hazards model of death as a function of IL-6 levels
(either categorized by the median or as a continuous variable). In
the multivariate analysis, the predefined models included those
variables significantly associated with death in univariate analyses.
In view of the limited size of the present cohort, supplementary Cox
regression analyses were performed including a propensity score
adjustment, which considers each individual’s probability of
exposure to measured, confounding variables (that is, age, CKD
stage, hemoglobin, and albumin), as detailed elsewhere.42 A P-value
p0.05 was considered to be statistically significant. All statistical
analyses were performed using SPSS (SPSS, Chicago, IL, USA),
version 13.0 for Windows (Microsoft Corp, Redmond, WA, USA).
The authors had full access to the data and take the responsibility
for its integrity. All authors have read and agree to the paper as
written.
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